Tysabri Could Hit $1.8B Sales

DOW JONES...READ MORE: "Stockbrokers says $1.6B in peak sales for suspended MS drug Tysabri are factored into the share price of over $14. It says $1.8B sales are achievable and gives a sum-of-the-parts valuation of up to $15.96. As Tysabri is under review by the FDA, NCB cautions, 'The risk of negative commentary ahead of the (FDA) panel's decision could generate negative sentiment.'"